

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER Medical Holdings Limited
希瑪醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3309)

POSITIVE PROFIT ALERT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of C-MER Medical Holdings Limited (the “**Company**” which together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the unaudited financial information currently available, profit attributable to equity holders of the Company for the six months ended 30 June 2025 (“**1H2025**”) is expected to be in the range of HK\$46.0 million to HK\$52.0 million, or an increase of around 49% to 69%, as compared with the profit attributable to equity holders of the Company of HK\$30.8 million for the same period last year.

The expected increase in profit attributable to shareholders of the Company was primarily driven by the slight increase of revenue to approximately HK\$940.0 million in 1H2025 from HK\$922.5 million for the same period last year and the effectiveness of our strategies to optimise our service network and enhance operating efficiency, which included the closure of non-performing operations and adoption of cost-saving measures.

As the Company is still in the process of finalising the results for 1H2025, the information contained in this announcement is based on the management’s preliminary review on the management accounts of the Group and current information available to the Board and has not been reviewed and confirmed by the Company’s auditors or the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the interim results announcement of the Company for 1H2025, which is expected to be published by the end of August 2025.

Shareholders and prospective investors of the Company are advised to exercise caution when dealings in the shares of the Company.

By order of the Board
C-MER Medical Holdings Limited
Ms. LI Xiaoting
*Vice Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, 19 August 2025

As at the date of this announcement, the Board comprises its chairman and independent non executive Director, Dr. Rex AU YEUNG Pak-kuen; two executive Directors, namely Ms. LI Xiaoting (Vice Chairman and Chief Executive Officer) and Dr. LEE Yau Wing Vincent; and five other independent non-executive Directors, namely Dr. KO Wing Man (Vice Chairman), Mr. MA Andrew Chiu Cheung, Mr. IP Shu Kwan Stephen, Mr. YIN Ke and Mr. LI Ling Cheung Raymond.